Multiple myeloma (MM) is a type of blood cancer that typically has no cure. Treatments like medications and stem cell ...
The FDA approved Sanofi's Sarclisa (isatuximab) in combination with VRd as a first-line treatment for newly diagnosed ...
Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated ...
The Food and Drug Administration (FDA) has approved Sarclisa ® (isatuximab-irfc) in combination with bortezomib, lenalidomide and dexamethasone (VRd) for the treatment of patients with newly diagnosed ...
The 21st annual meeting of the International Myeloma Society takes place September 25-28, 2024, in Rio de Janiero, Brazil.
Approval based on positive results from the IMROZ phase 3 study demonstrating Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) significantly improved progression-free ...
The FDA approved isatuximab plus bortezomib, lenalidomide, and dexamethasone for patients with newly diagnosed myeloma who ...
The FDA has approved Sarclisa (isatuximab) as a first-line therapy for blood cancer multiple myeloma as a combination regimen ...
The median progression-free survival (PFS ... by the FDA in 2020 in combination with pomalidomide and dexamethasone for ...
The principal goal of therapies for multiple myeloma, which remains incurable, is to extend progression-free survival, but challenges remain bringing chimeric antigen receptor T-cell therapy to the ...
The approval is supported by data from the phase 3 IMROZ study which demonstrated superior progression-free survival with ...
US FDA approves anti-CD38 therapy, Sarclisa in combo with standard-of-care treatment for adult patients with NDMM who are not eligible for transplant: Paris Tuesday, September 24, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback